P. Olesen

发表

1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists.

L Jeppesen, J S Ward, F. Bymaster, 1998, Journal of medicinal chemistry.

Small-molecule agonists for the glucagon-like peptide 1 receptor

Jeppe Sturis, Jarek Kostrowicki, Carsten Behrens, 2007, Proceedings of the National Academy of Sciences.

Agonists at the alpha4beta2 nicotinic acetylcholine receptors: structure-activity relationships and molecular modelling.

P. Olesen, J. E. Tønder, 2001, Current medicinal chemistry.

Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease

F. Bymaster, L. Farde, P. Suzdak, 1997 .

Insulins with built‐in glucose sensors for glucose responsive insulin release

S. Havelund, L. Schäffer, T. Hoeg-Jensen, 2005, Journal of peptide science : an official publication of the European Peptide Society.

Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor.

J. Holst, J. D. de Jong, Michael D. Johnson, 2007, Bioorganic & medicinal chemistry letters.

Muscarinic agonists as analgesics. Antinociceptive activity versus M1 activity: SAR of alkylthio-TZTP's and related 1,2,5-thiadiazole analogs.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1995, Life sciences.

Xanomeline: An Efficacious and Specific M1 Receptor Agonist — Preclinical Update

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1994 .

Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndrome.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1997, Journal of medicinal chemistry.

Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.

D. Wong, F. Bymaster, P. Suzdak, 1994, The Journal of pharmacology and experimental therapeutics.

Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.

I. Pettersson, K. Rimvall, P. Olesen, 1999, Journal of medicinal chemistry.

Heterocyclic studies. 2. 5‐Chloro‐1H‐1,2,3‐triazole‐4‐carboxaldehydes, preparation and rearrangement reactions

E. Pedersen, J. Becher, F. Nielsen, 1984 .

Pyridazines with heteroatom substituents in position 3 and 5. 2. Regioselective introduction of mercapto groups in pyridazines

J. Becher, T. Kappe, P. Olesen, 1988 .

Biomimetic Systems for the “Visible” Copper‐Site CuA in Cytochrome c Oxidase

J. Becher, J. Pedersen, H. Toftlund, 1985 .

3-(5-Alkylamino-4-isoxazolyl)-1,2,5,6-tetrahydropyridines: a novel class of central nicotinic receptor ligands.

Michael D B Swedberg, K. Rimvall, P. Olesen, 1998, Bioorganic & medicinal chemistry.

Thieno[2,3-b]indole. The unsubstituted ring system

P. Olesen, J. Hansen, M. Engelstoft, 1995 .

Preparation of heterocyclic thialato ligands and their Copper(II) complexes

J. Becher, H. Toftlund, P. Olesen, 1985 .

A general route to thiolato ligands via t-butyl sulphides

J. Becher, H. Toftlund, P. Olesen, 1983 .

Synthesis of Sulfonyl Chlorides of Phenylboronic Acids

T. Hoeg-Jensen, P. Olesen, P. Vedsø, 2004 .

Butylthio[2.2.2] (NNC 11-1053/LY297802): an orally active muscarinic agonist analgesic.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1997, The Journal of pharmacology and experimental therapeutics.

M1 receptor agonist activity is not a requirement for muscarinic antinociception.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1997, The Journal of pharmacology and experimental therapeutics.

Novel functional M1 selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore.

J S Ward, M L Lamb, F. Bymaster, 1992, Journal of medicinal chemistry.

Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .

J S Ward, F. Bymaster, A. Pike, 1992, Journal of medicinal chemistry.

Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors.

B. Ursø, B. Hansen, Preben H Olesen, 2003, Journal of medicinal chemistry.

The use of bioisosteric groups in lead optimization.

P. Olesen, P H Olesen, 2001, Current opinion in drug discovery & development.

Potential role of muscarinic receptors in schizophrenia.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1999, Life sciences.

Inverse isostere strategies in the development of cholinergic agonists with multiple therapeutic potentials

F. Bymaster, Michael D B Swedberg, C. Mitch, 1997 .

Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity.

D. Wong, F. Bymaster, P. Suzdak, 1997, The Journal of pharmacology and experimental therapeutics.

3-(3-Alkylthio- 1,2,5-thiadiazol-4-yl)- 1 -azabicycles. Structure-activity relationships for antinociception mediated by central muscarinic receptors

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1996 .

Analgesic Effects of Vedaclidine, a Mixed Agonist ‚Äì Antagonist at Muscarinic Receptor Subtypes

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2003 .

In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1997, Life sciences.

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1998, European journal of pharmacology.

Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activation.

F. Bymaster, A. Fink-Jensen, J. Ward, 1998, Bioorganic & Medicinal Chemistry Letters.

Synthesis and structural determination of stereoisomers of muscarinic ligands of the (3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicycloalkane type.

C. Mitch, J. Deeter, J. Ward, 1997, Chirality.

Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).

D. Wong, F. Bymaster, P. Suzdak, 1994, The Journal of pharmacology and experimental therapeutics.

SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIPS OF ALKYL SUBSTITUTED ANALOGUES OF THE FUNCTIONAL M1 SELECTIVE MUSCARINIC RECEPTOR AGONIST XANOMELINE

F. Bymaster, P. Suzdak, C. Mitch, 1994 .

Novel Functional M1 Selective Muscarinic Agonists. Synthesis and Structure→Activity Relationships of 3‐(1,2,5‐Thiadiazolyl)‐1,2,5,6‐tetrahydro‐1‐methylpyridines.

F. Bymaster, A. Pike, C. Mitch, 1992 .

Heterocyclic Studies — Part 1. Synthesis of Thieno[2,3-d]triazoles

J. Becher, P. Olesen, A. Gakh, 1986 .

Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors.

Lars Naerum, Preben H Olesen, P. Olesen, 2002, Bioorganic & medicinal chemistry letters.

An improved nicotinic pharmacophore and a stereoselective CoMFA-model for nicotinic agonists acting at the central nicotinic acetylcholine receptors labelled by [3H]-N-methylcarbamylcholine

Ingrid Pettersson, John Bondo Hansen, Janne E. Tønder, 2001, J. Comput. Aided Mol. Des..

Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.

J S Ward, F. Bymaster, Michael D B Swedberg, 1995, Journal of medicinal chemistry.